Serina Therapeutics, Inc.

Contributing Author

Recent Articles by Serina Therapeutics, Inc.

Apr-07	Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit SER GlobeNewswire
Apr-02	Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan SER GlobeNewswire
Mar-25	Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights SER +24.69% SER -13.86% GlobeNewswire
Mar-24	Serina Therapeutics to Present at the 38th Annual Roth Conference SER -22.86% GlobeNewswire
Mar-18	Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease SER +93.75% SER GlobeNewswire
Feb-24	Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease SER +6.37% SER +5.99% GlobeNewswire
Feb-19	Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease SER GlobeNewswire
Feb-03	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event SER GlobeNewswire
Jan-28	Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease SER +30.15% SER GlobeNewswire
Jan-15	Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity SER +15.24% SER GlobeNewswire
Dec-11	Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry SER GlobeNewswire
Dec-10	Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program SER GlobeNewswire
Nov-13	Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights SER GlobeNewswire
Nov-03	Serina Therapeutics Provides Regulatory Update on SER-252 Program SER -6.40% GlobeNewswire
Oct-08	Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors SER GlobeNewswire
Oct-06	Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease SER GlobeNewswire
Sep-09	Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease SER -6.34% SER GlobeNewswire
Sep-08	Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference SER GlobeNewswire
Aug-25	Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway SER GlobeNewswire
Aug-11	Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights SER -7.44% SER +7.06% GlobeNewswire
Jul-29	Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) SER GlobeNewswire
Jul-28	Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference SER +5.83% GlobeNewswire
Jul-10	Serina Therapeutics Makes Grant to New Employee Under Inducement Plan SER GlobeNewswire
Jul-01	Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting SER GlobeNewswire
Jun-23	Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025 SER +5.95% GlobeNewswire
Jun-17	UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 SER GlobeNewswire
Jun-17	Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 SER GlobeNewswire
Jun-09	Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" SER GlobeNewswire
May-22	Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors SER +8.87% GlobeNewswire
May-14	Serina Therapeutics Makes Grants to New Employees Under Inducement Plan SER GlobeNewswire
May-08	Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights SER GlobeNewswire

Serina Therapeutics, Inc.

Recent Articles by Serina Therapeutics, Inc.

Upgrade your Finviz experience